ERG protein expression in human tumors detected with a rabbit monoclonal antibody

American Journal of Clinical Pathology

Volumn 138, Issue 6, 2012, Pages 803-810

  Yaskiv, Oksana ^a,b   Rubin, Brian P ^a   He, Huiying ^a,c   Falzarano, Sara ^a   Magi Galluzzi, Cristina ^a   Zhou, Ming ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b North Shore Long Island Jewish Health System ^*  (United States)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ERG; Immunohistochemistry; Meningioma; Prostate carcinoma; Vascular lesion

Indexed keywords

MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR ERG;

ADULT; ARTICLE; CANCER DIAGNOSIS; EPITHELIUM TUMOR; ERYTHROBLASTOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; VASCULAR LESION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASMS; PROSTATIC NEOPLASMS; RABBITS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR NEOPLASMS;

EID: 84869221353     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP3K5VUFALZTKC     Document Type: Article

References (37)

1. Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res. 1998;75:1-55. (Pubitemid 28429032)
2. Sharrocks AD, Brown AL, Ling Y, et al. The ETS-domain transcription factor family. Int J Biochem Cell Biol. 1997;29:1371-1387. (Pubitemid 28153488)
3. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;6:429-439.
4. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
5. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-4711.
6. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275-286.
7. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648. (Pubitemid 41528150)
8. Esgueva R, Perner S, LaFargue CJ, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010;23:539-546.
9. Falzarano SM, Navas M, Simmerman K, et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol. 2010;23:1499-1506.
10. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011;459:441-447.
11. Falzarano SM, Zhou M, Hernandez AV, et al. Single focus prostate cancer: pathological features and ERG fusion status. J Urol. 2011;185:489-494.
12. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2008;21:67-75. (Pubitemid 351172158)
13. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-237.
14. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011;35:432-441.
15. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061-1067.
16. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/ P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35:1062-1068.
17. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590-598.
18. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008;111:3498-3506.
19. Mohamed AA, Tan SH, Mikhalkevich N, et al. ETS family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer. 2010;1:197-208.
20. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer." Am J Surg Pathol. 2011;35:608-614.
21. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008;14:3380-3385.
22. Lin BT, Colby T, Gown AM, et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma: a report of 14 cases. Am J Surg Pathol. 1996;20:1431-1439. (Pubitemid 26411710)
23. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol. 1994;7:82-90.
24. Folpe AL, Veikkola T, Valtola R, et al. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000;13:180-185. (Pubitemid 30109106)
25. Traweek ST, Kandalaft PL, Mehta P, et al. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol. 1991;96:25-31.
26. Folpe AL, Chand EM, Goldblum JR, et al. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25:1061-1066. (Pubitemid 32685904)
27. Rossi S, Orvieto E, Furlanetto A, et al. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol. 2004;17:547-552. (Pubitemid 38868421)
28. Itakura E, Yamamoto H, Oda Y, et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74-81.
29. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86:2406-2412. (Pubitemid 30010384)
30. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-394. (Pubitemid 29094089)
31. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol. 2000;13:536-541. (Pubitemid 30332105)
32. Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene. 2000;19:6464-6471. (Pubitemid 32108436)
33. Kachra Z, Beaulieu E, Delbecchi L, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis. 1999;17:555-566. (Pubitemid 30337129)
34. Nordqvist AC, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg. 2001;95:839-844. (Pubitemid 33043358)
35. Okada M, Miyake K, Matsumoto Y, et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol. 2004;66:29-37. (Pubitemid 38259817)
36. Okuducu AF, Zils U, Michaelis SA, et al. Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology. 2006;48:836-845. (Pubitemid 43800944)
37. Okuducu AF, Zils U, Michaelis SA, et al. Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer. 2006;107:1365-1372. (Pubitemid 44452787)